These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment]. Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737 [TBL] [Abstract][Full Text] [Related]
6. [Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment]. Qiu YG; Yao XY; Tao QM; Zheng P; Chen JZ; Zhu JH; Zhang FR; Zheng LR; Zhao LL Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Aug; 25(8):710-4. PubMed ID: 15555399 [TBL] [Abstract][Full Text] [Related]
7. ESH-ESC guidelines for the management of hypertension. Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473 [TBL] [Abstract][Full Text] [Related]
8. [Antihypertensive therapy in the nineties]. Weidmann P; Ferrari P Schweiz Rundsch Med Prax; 1992 Feb; 81(7):188-98. PubMed ID: 1535954 [TBL] [Abstract][Full Text] [Related]
9. Treatment of hypertension in chronic kidney disease. Toto RD Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269 [TBL] [Abstract][Full Text] [Related]
10. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy. Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C; Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142 [TBL] [Abstract][Full Text] [Related]
12. [Arterial hypertension difficult to control in the elderly patient. The significance of the "white coat effect"]. Amado P; Vasconcelos N; Santos I; Almeida L; Nazaré J; Carmona J Rev Port Cardiol; 1999 Oct; 18(10):897-906. PubMed ID: 10590654 [TBL] [Abstract][Full Text] [Related]
13. Major new developments affecting treatment and prognosis in hypertension. Gubner RS Trans Assoc Life Insur Med Dir Am; 1990; 73():97-114. PubMed ID: 2353405 [TBL] [Abstract][Full Text] [Related]
14. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2. Ekbom T; Linjer E; Hedner T; Lanke J; De Faire U; Wester PO; Dahlöf B; Scherstén B Blood Press; 2004; 13(3):137-41. PubMed ID: 15223721 [TBL] [Abstract][Full Text] [Related]
15. The future of antihypertensive treatment. Israili ZH; Hernández-Hernández R; Valasco M Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579 [TBL] [Abstract][Full Text] [Related]
16. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. Khan NA; McAlister FA; Lewanczuk RZ; Touyz RM; Padwal R; Rabkin SW; Leiter LA; Lebel M; Herbert C; Schiffrin EL; Herman RJ; Hamet P; Fodor G; Carruthers G; Culleton B; DeChamplain J; Pylypchuk G; Logan AG; Gledhill N; Petrella R; Campbell NR; Arnold M; Moe G; Hill MD; Jones C; Larochelle P; Ogilvie RI; Tobe S; Houlden R; Burgess E; Feldman RD; Can J Cardiol; 2005 Jun; 21(8):657-72. PubMed ID: 16003449 [TBL] [Abstract][Full Text] [Related]
17. [Are all antihypertensive drugs renoprotective?]. Wolf S; Risler T Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950 [TBL] [Abstract][Full Text] [Related]
19. [Hypertension management in general practice in Iceland]. Jensdóttir JO; Sigurethsson EL; Thornorgeirsson G Laeknabladid; 2006 May; 92(5):375-80. PubMed ID: 16741320 [TBL] [Abstract][Full Text] [Related]
20. Left ventricular hypertrophy: how to influence an important risk factor in hypertension. Agabiti-Rosei E; Muiesan ML J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]